| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial
|
Bellmunt, Joaquim
|
|
|
22 |
4 |
p. 525-537
|
artikel
|
| 2 |
Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis
|
Copland, Emma
|
|
|
22 |
4 |
p. 558-570
|
artikel
|
| 3 |
Are taxanes the future for head and neck cancer? Pragmatism in the immunotherapy era
|
Hwang, Michael
|
|
|
22 |
4 |
p. 413-415
|
artikel
|
| 4 |
A southeast Asia perspective on medical imaging and nuclear medicine
|
Chamroonrat, Wichana
|
|
|
22 |
4 |
p. 426-427
|
artikel
|
| 5 |
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
|
Lee, Nancy Y
|
|
|
22 |
4 |
p. 450-462
|
artikel
|
| 6 |
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial
|
Guigay, Joël
|
|
|
22 |
4 |
p. 463-475
|
artikel
|
| 7 |
Correction to Lancet Oncol 2021; 22: 413–15
|
|
|
|
22 |
4 |
p. e134
|
artikel
|
| 8 |
COVID-19 and cancer: 1 year on
|
The Lancet Oncology,
|
|
|
22 |
4 |
p. 411
|
artikel
|
| 9 |
De-escalation of breast and axillary surgery in exceptional responders to neoadjuvant systemic treatment
|
Heil, Joerg
|
|
|
22 |
4 |
p. 435-436
|
artikel
|
| 10 |
Elucidating the association between antihypertensive drugs and cancer: a need for real-world studies
|
Azoulay, Laurent
|
|
|
22 |
4 |
p. 421-422
|
artikel
|
| 11 |
70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age
|
Piccart, Martine
|
|
|
22 |
4 |
p. 476-488
|
artikel
|
| 12 |
Genetic variation in cervical preinvasive and invasive disease: a genome-wide association study
|
Bowden, Sarah J
|
|
|
22 |
4 |
p. 548-557
|
artikel
|
| 13 |
Genomic characterisation of cervical cancer and human papillomavirus: new opportunities for precision medicine
|
Franceschi, Silvia
|
|
|
22 |
4 |
p. 419-420
|
artikel
|
| 14 |
Georgina Sposetti: trial recruitment revolutionary
|
Lucas, Catherine
|
|
|
22 |
4 |
p. 438
|
artikel
|
| 15 |
Global access to medical imaging and nuclear medicine
|
Lapi, Suzanne E
|
|
|
22 |
4 |
p. 425-426
|
artikel
|
| 16 |
How can we achieve equitable global access to cancer imaging and care?
|
Montag, Bernhard
|
|
|
22 |
4 |
p. 429-430
|
artikel
|
| 17 |
Imaging: towards a global solution to overcome the cancer pandemic
|
Borget, Isabelle
|
|
|
22 |
4 |
p. 430-432
|
artikel
|
| 18 |
Improving the view: the need for global action on universal access to cancer imaging
|
Gourd, Katherine
|
|
|
22 |
4 |
p. 422-423
|
artikel
|
| 19 |
Medical imaging and nuclear medicine: a Lancet Oncology Commission
|
Hricak, Hedvig
|
|
|
22 |
4 |
p. e136-e172
|
artikel
|
| 20 |
MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study
|
Pötter, Richard
|
|
|
22 |
4 |
p. 538-547
|
artikel
|
| 21 |
ODA budget cuts will affect global cancer research
|
Burki, Talha Khan
|
|
|
22 |
4 |
p. e135
|
artikel
|
| 22 |
Pembrolizumab monotherapy in metastatic triple-negative breast cancer
|
Amir, Eitan
|
|
|
22 |
4 |
p. 415-417
|
artikel
|
| 23 |
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study
|
Kuruvilla, John
|
|
|
22 |
4 |
p. 512-524
|
artikel
|
| 24 |
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
|
Winer, Eric P
|
|
|
22 |
4 |
p. 499-511
|
artikel
|
| 25 |
Pushing the boundaries of computer-aided diagnosis of melanoma
|
Geraldes, Flávia Oliveira
|
|
|
22 |
4 |
p. 433
|
artikel
|
| 26 |
Relapsed or refractory classical Hodgkin lymphoma: which immunotherapy, and when?
|
Vassilakopoulos, Theodoros P
|
|
|
22 |
4 |
p. 417-419
|
artikel
|
| 27 |
RETRACTED: Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
|
Rugo, Hope S
|
|
|
22 |
4 |
p. 489-498
|
artikel
|
| 28 |
Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial
|
Shi, Tingyan
|
|
|
22 |
4 |
p. 439-449
|
artikel
|
| 29 |
Should we or should we not? Secondary debulking in ovarian cancer
|
Richardson, Debra L
|
|
|
22 |
4 |
p. 412-413
|
artikel
|
| 30 |
Stereotactic radiotherapy and oligometastases
|
Macbeth, Fergus
|
|
|
22 |
4 |
p. e132
|
artikel
|
| 31 |
Stereotactic radiotherapy and oligometastases – Authors' reply
|
Chalkidou, Anastasia
|
|
|
22 |
4 |
p. e133
|
artikel
|
| 32 |
Symmetric bilateral liposarcoma in an interventional cardiologist
|
Gunsilius, Eberhard
|
|
|
22 |
4 |
p. e173
|
artikel
|
| 33 |
The benefits of integrating medical imaging and nuclear medicine
|
Murphy, Kieran
|
|
|
22 |
4 |
p. 427-429
|
artikel
|
| 34 |
The Great Secret: chemotherapy's fiery birth
|
Lokody, Isabel
|
|
|
22 |
4 |
p. 437
|
artikel
|
| 35 |
The importance of medical imaging and nuclear medicine in universal health coverage
|
Grossi, Rafael Mariano
|
|
|
22 |
4 |
p. 423-424
|
artikel
|
| 36 |
UK charities call for emergency government funding
|
Das, Manjulika
|
|
|
22 |
4 |
p. 434
|
artikel
|
Tijdschrift beschrijving